Its expression is elevated in MASLD patients, and various stimuli can exacerbate liver steatosis via NF-kB signaling, Inhibition of its activity ameliorates hepatic steatosis (106–108). Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.